Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of satralizumab in pediatric AQP4 antibody-positive NMOSD
2023-507817-85-00Phase 3Authorised
- Sponsor
- Roche
- Start
- Jul 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 8
01
Overview
Phase 3, open-label, single-arm trial of satralizumab in neuromyelitis optica spectrum disorder (NMOSD), sponsored by Roche. Primary endpoints: Observed serum satralizumab trough concentrations and Population pharmacokinetic parameters. Planned start Jul 2024; status: authorised.
02
Drugs
satralizumab
03
Conditions
neuromyelitis optica spectrum disorder (NMOSD)
Beyond the preview
Go deeper on 2023-507817-85-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507817-85-00.